Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1

Interventions

pembrolizumab 521Specimen Handling 383Carboplatin 376Magnetic Resonance Spectroscopy 334Cisplatin 331Nivolumab 309Cyclophosphamide 298Radiotherapy 257Paclitaxel 254Biopsy 235Gemcitabine 234Bevacizumab 218Dexamethasone 169durvalumab 167Oxaliplatin 163Capecitabine 159Rituximab 156Fluorouracil 149venetoclax 147Docetaxel 147atezolizumab 143Drug Therapy 143Etoposide 141Doxorubicin 134Ipilimumab 129Prednisone 121Radiosurgery 120Lenalidomide 118Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Janus Kinase Inhibitors × 1 year × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06715982 2025-10-28

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Hangzhou Cancer Hospital

Phase 2 Recruiting
35 enrolled

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡